# SAFFRON (NCT05261399)

> Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05261399
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma; Non-Small-Cell Lung
- Interventions: Savolitinib; Osimertinib; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 341
- Primary outcome: Progression-free survival (PFS) / savolitinib + osimertinib versus platinum doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on osimertinib.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=saffron-nct05261399